
About Femasys
Femasys is a publicly listed company based in Atlanta (United States) founded in 2004. Medical devices for womens healthcare are developed and provided. It operates on a Direct-to-Consumer (D2C) and HealthTech model. Femasys has raised $69.22 million across 18 funding rounds from investors including Salem Partners, PharmaCyte Biotech and Legacy Capital Advisors, LLC. The company has 71 employees. Femasys offers products and services including FemaSeed, FemVue, FemBloc, and FemCerv. Its focus areas include Medical Devices and Women's Health Devices. Its legal entity is Femasys Inc. Its competitors include Daré Bioscience, MTM Laboratories and Teal Health; 2 of its 3 listed competitors have raised funding.
Company details
Femasys is engaged in creating next-generation medical devices and solutions targeting underserved areas in womens health. The company is dedicated to addressing critical needs in infertility, birth control, and cancer diagnosis. Products such as FemaSeed, FemVue, and FemBloc are developed to provide transformative healthcare options. Safety and high standards of care are prioritized in all offerings. The focus is maintained on global unmet needs within the healthcare sector for women.
- Headquarters Atlanta, United States
- Employees 71
- Stage Public
- SectorsHealthcare
- Phone•••• ••••
- Website femasys.com
- Social LinkedIn X Facebook
- Legal Name Femasys Inc.
- Annual Revenue$2.29 M (USD)40.77as on Dec 31, 2025
- Net Profit-$18.63 M (USD)1as on Dec 31, 2025
- EBITDA-$16.74 M (USD)1.04as on Dec 31, 2025
- Total Equity Funding$69.22M (USD)
in 18 rounds
- Latest Funding Round$30M (USD), Post-IPO
Aug 2026
- InvestorsSalem Partners
& 4 more
- Employee Count71
Products & Services of Femasys
Femasys offers a comprehensive portfolio of products and services, including FemaSeed, FemVue, FemBloc, and FemCerv.
Innovative solution for infertility treatment in women provided.
Diagnostic tool for infertility assessment in women offered.
Permanent birth control solution for women is developed.
Tool for cervical cancer diagnosis in women provided.
Funding Insights of Femasys
Femasys has successfully raised a total of $69.22M across 18 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $69.22M
- Total Rounds 18
- Last Round Post-IPO — $30M
- First Round $2.29M
(Sep 2005)
- Investors Count 5
Latest 10 of 18 funding rounds of Femasys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2026 | $30M | Post-IPO | – | Nantahala Capital Management | |
| Nov 2025 | $8.03M | Post-IPO | – | – | – |
| Jun 2025 | $1.45M | Post-IPO | – | – | – |
| Nov 2023 | $6.85M | Post-IPO | – | – | |
| Jan 2017 | $4M | Series C | – | – | – |
| Dec 2016 | $40M | Series C | – | Salem Partners | – |
| Jul 2016 | $3.3M | Series B | – | – | – |
| Jul 2016 | Debt – Conventional | – | – | – | |
| Apr 2015 | $10.2M | Series B | – | Legacy Capital Advisors, LLC | |
| Sep 2013 | $180,000 | Series A | – | – | – |
5 investors in total: 5 institutional.
Investors in Femasys
Femasys has secured backing from 5 investors, including institutional investors. Prominent investors backing the company include Salem Partners, PharmaCyte Biotech and Legacy Capital Advisors, LLC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of targeted therapeutics for cancer and diabetes | 1996 | pharmacyte.com | Silver Spring, United States | |
Regional investment bank | 1997 | salempartners.com | Los Angeles, United States | |
| nantahalapartners.com | ||||
| rosalindcap.com | ||||
| yourlegacyteam.net |
Investor details for Femasys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Femasys
20 people are tracked at Femasys (9 in leadership, 4 in board & advisors, 7 in team); the tracked headcount is 71.
| Name | Role | Group |
|---|---|---|
Amy Beaulieu Rohner | Senior Director, Finance And Administration | Leadership |
Terrell A. Pruitt | VP, Manufacturing | Leadership |
Dov Elefant | CFO | Leadership |
Mary An Merchant | VP Counsel, Intellectual Poperty | Leadership |
Jeremy Sipos | VP, Research & Development | Leadership |
Jeffrey Marcus | Chief Medical Advisor | Leadership |
Kathy Lee-Sepsick | President, CEO & Director | Leadership |
Valerie Ammons Dawydiak | West Director Of Sales | Leadership |
Kayla Carlton | Director, Commercial Excellence | Leadership |
Alistair Milnes | Board Member | Board & advisors |
Keith J. Kendall | Board Member | Board & advisors |
Edward Uzialko, Jr. | Member | Board & advisors |
Charles Larsen | Member | Board & advisors |
Christine Thomas | SVP of Regulatory & Clinical Affairs | Team |
Richard Spector | Commercial Advisor | Team |
Daniel Currie | SVP, Operations | Team |
Farhan Rahman | Associate Product Development Engineer | Team |
Yeisa Whaley | Quality Assurance Manager | Team |
Dongkun H. | Sr. Chemical Development Engineer | Team |
Heidi Volk | Human Resources Manager | Team |
Complete people profiles for Femasys
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Femasys
Femasys is a publicly listed company on the NASDAQ with ticker symbol FEMY in USA, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jun 2021
- Listed onNASDAQ: FEMY
- Listed entityFemasys Inc.
- Exchange sectorElectronic technology
- ISINUS31447E2046
- Share price$1.76 (+0.57% on the day) · 2026-10-13
- Market capitalisation$14.7M
- EPS (diluted, trailing year)$-4.62
- Volume (last session)35,474
Financials of Femasys
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $2.3M | -$18.6M | -$16.7M |
| 2024 | $1.6M | -$18.8M | -$16.9M |
| 2023 | $1.1M | -$14.2M | -$13.6M |
| 2022 | $1.2M | -$11.4M | -$10.7M |
| 2021 | $1.2M | -$7.5M | -$7.4M |
Detailed financial statements for Femasys
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Femasys
4 dated milestones of Femasys across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Femasys is founded.
- Funding First funding round of $2.3M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $30.0M.
Competitors of Femasys
Femasys has 3 listed competitors in our database, 2 of them funded. They include Daré Bioscience, MTM Laboratories and Teal Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| darebioscience.com | 2005 | San Diego, United States | 30 | Non-hormonal pharmaceutical products for female contraceptives are developed. | ||
| mtm-laboratories.com | 1999 | Tucson, United States | $76.07M | In vitro diagnostics for early cervical cancer detection are manufactured. | ||
| getteal.com | 2020 | San Francisco, United States | $43.25M | 6 | Cervical cancer screening kits are provided by Teal Health. |
Detailed competitors of Femasys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Femasys
The website of Femasys (femasys.com) receives about 9.3K visits a month.
- Monthly visits9.3K
▼ 29.3% vs previous month
Top companies in Women's Health & Fertility
3 companies that operate in the same segment as Femasys (Women's Health & Fertility) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of cell-free DNA testing for oncology, women’s health, and organ health | 2004 | Redwood City, California, United States | USD 152.1 M | USD 2.31 B | 4,430 | |
Therapeutics for women's healthcare are developed and offered. | 1997 | Princeton, New Jersey, United States | USD 123.06 M | USD 19.59 M | ||
Provider of cell-free cancer liquid biopsy test | 2015 | San Francisco, California, United States | USD 388.62 M | 861 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Femasys
Complete news archive for Femasys
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Femasys
Femasys was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Femasys is headquartered in Atlanta, United States. It is registered at Atlanta, Georgia, United States.
Femasys is a funded company, having raised a total of $69.22M across 18 funding rounds to date. The company's 1st funding round was a Series A of $180K, raised on Sep 2005.
Femasys has 71 employees.
Annual revenue of Femasys is $2.29M as on Dec 31, 2025.
Femasys is engaged in creating next-generation medical devices and solutions targeting underserved areas in womens health. The company is dedicated to addressing critical needs in infertility, birth control, and cancer diagnosis. Products such as FemaSeed, FemVue, and FemBloc are developed to provide transformative healthcare options. Safety and high standards of care are prioritized in all offerings. The focus is maintained on global unmet needs within the healthcare sector for women.
Femasys's top competitors include Daré Bioscience, Teal Health and MTM Laboratories.
Femasys offers FemaSeed, FemVue, FemBloc, and FemCerv.
Yes, Femasys is publicly traded on NASDAQ under the ticker symbol FEMY.
Femasys has 5 investors. Key investors include Salem Partners, PharmaCyte Biotech, Legacy Capital Advisors, LLC, Nantahala Capital Management, and Rosalind Advisors.
Femasys operates through Femasys Inc..
